The Business of Biofabrication

CollPlant Biotechnologies (NASDAQ: CLGN), a leader in recombinant human collagen (rhCollagen) innovation, has appointed Bowman Bagley as Vice President, Commercial North America. The newly created position underscores CollPlant’s growing commitment to scaling its regenerative medicine and bioprinting platforms across the U.S. and Canadian markets.

Leadership with Deep Roots in Biomaterials

Bagley, an experienced executive in collagen-based biomaterials and 3D bioprinting, brings extensive experience from his leadership role at Advanced BioMatrix. At ABM, he served as CEO and was instrumental in transforming the company into a trusted global supplier for collagen and ECM products in the research and tissue engineering sectors.

“Bowman’s technical and commercial expertise in biomaterials is precisely what we need as we accelerate the rollout of our rhCollagen platforms,” said CollPlant CEO Yehiel Tal. “He’ll play a pivotal role in driving commercial adoption of our bioinks and regenerative solutions for both aesthetics and tissue engineering.”

Scaling rhCollagen Innovation

In his new role, Bagley will oversee North American sales, marketing, and operational strategy. His hiring comes at a time when CollPlant is ramping up strategic partnerships and exploring broader market penetration opportunities. The company’s rhCollagen, derived from a proprietary tobacco plant-based system, is gaining traction as a viable, non-animal alternative for tissue regeneration and 3D bioprinting.

Bagley expressed enthusiasm about joining the company during a phase of significant growth. “CollPlant is reshaping the future of regenerative medicine,” he said. “I’m thrilled to contribute to a team that’s delivering real translational impact with its rhCollagen platform.”

A Broader Strategic Vision

This appointment follows a string of strategic moves by CollPlant, including its development and commercialization partnership with AbbVie for rhCollagen-based dermal fillers. The company is also advancing next-generation implantable bioprinted tissues and exploring additional applications in breast implants and soft tissue repair.

As North America becomes a focal point in CollPlant’s commercialization roadmap, Bagley’s leadership is expected to catalyze new partnerships, research collaborations, and market expansion efforts—particularly in the growing intersection between 3D bioprinting and regenerative aesthetics.

About CollPlant

CollPlant Biotechnologies is a regenerative and aesthetic medicine company pioneering a platform based on non-animal recombinant human collagen (rhCollagen) produced via plant-based technology. Its products address clinical needs in tissue repair, organ manufacturing, and aesthetics. CollPlant has active partnerships with global leaders, including AbbVie, and is advancing 3D bioprinting programs for functional tissues and soft tissue regeneration.

This article reflects publicly available information as of the date of publication and does not contain forward-looking statements or financial projections.

For more information visit the original article from where quotes where taken here.